Inactive Instrument
ReNeuron Group plc Stock
Stocks
RENE
GB00BF5G6K95
Biotechnology & Medical Research
OTC Markets Traded
| 24-02-06 | RENEURON ISSUES ADMINISTRATION WARNING | AQ |
| 23-11-27 | Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ | EQ |
| 23-11-16 | ReNeuron : Interim Statement 2023 | PU |
| 23-11-07 | ReNeuron : Presentation | PU |
| 23-07-24 | ReNeuron : 24 July 2023 – Notice of Annual General Meeting | PU |
| 1 day | -2.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2025-03-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Iain Ross
CHM | Chairman | 72 | 2021-06-30 |
| Director/Board Member | 63 | 2021-07-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/12/23 | Buy | Chief Financial Officer | 52,332 | 0.0915% | ||
| 6/16/23 | Buy | Director | 150,000 | 0.2624% | ||
| 6/16/23 | Buy | Chairman | 150,000 | 0.2624% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17% | -11.18% | - | - | 2.58M | |
| +0.59% | +3.31% | +1.03% | +24.53% | 46.28B | |
| +1.30% | +3.10% | +44.15% | +31.38% | 43.85B | |
| +0.95% | -5.40% | +342.72% | +548.37% | 40.93B | |
| +4.23% | +5.53% | +9.35% | +89.62% | 39.89B | |
| +1.11% | +1.80% | +11.52% | +43.15% | 29.5B | |
| +1.94% | +6.24% | +25.19% | +145.07% | 17.09B | |
| +0.37% | -9.84% | - | - | 15.55B | |
| +2.12% | +10.41% | +24.78% | +39.05% | 15.22B | |
| +0.24% | +32.23% | -11.57% | - | 14.05B | |
| Average | +1.06% | +3.97% | +55.90% | +131.60% | 29.15B | |
| Weighted average by Cap. | +1.54% | +2.08% | +70.37% | +141.24% |
Employees
26
